Flex Pharma (FLKS) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Flex Pharma Reports Second Quarter 2016 Financial Results
August 3, 2016 7:00 AM EDT-- Single Agent Human Efficacy Study in NLC Fully Enrolled Ahead of Plan with Topline Results Expected by Year End --
-- Phase 2 MS Study of FLX-787 Initiated in June; Phase 2 ALS Study to Start in the Coming Months --
-- First Consumer Product Scientifically Proven to Treat and Prevent Muscle Cramps Launched in June --
Conference Call Scheduled Today at 8:45 a.m. ET
BOSTON--(BUSINESS WIRE)--... More
